EGFR and non-small cell lung carcinoma: Following IPASS, several landmark trials have confirmed the superiority of gefitinib over platinum-doublet in the first-line setting for patients with EGFR-mutant NSCLC in East Asian (NEJ-002, WJTOG3405) and White patients (IFUM) (Table 1) [27,28,29,30,31].